Category Archives: Tms

LOS ANGELES, United States: QY Research offers an overarching research and analysis-based study on, Global Transportation Management System (TMS) Solution Market Report, History and Forecast 2016-2027, Breakdown Data by Companies, Key Regions, Types and Application. Analysts have used primary and secondary research methodologies to determine the path of the market. The data includes historic and forecast values for a well-rounded understanding.The researchers and analysts who have prepared the report used an advanced research methodology and authentic primary and secondary sources of market information and data. It is a phenomenal compilation of important studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the global Transportation Management System (TMS) Solution market. Players can use the accurate market facts and figures and statistical studies provided in the report to understand the current and future growth of the global Transportation Management System (TMS) Solution market. The report offers an in-depth assessment of key market dynamics, the competitive landscape, segments, and regions in order to help readers to become better familiar with the global Transportation Management System (TMS) Solution market.

This report includes assessment of various drivers, government policies, technological innovations, upcoming technologies, opportunities, market risks, restrains, market barriers, challenges, trends, competitive landscape, and segments which gives an exact picture of the growth of the global Transportation Management System (TMS) Solution market.

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Transportation Management System (TMS) Solution market.

Key questions answered in the report:

TOC

1 Market Overview of Transportation Management System (TMS) Solution1.1 Transportation Management System (TMS) Solution Market Overview1.1.1 Transportation Management System (TMS) Solution Product Scope1.1.2 Market Status and Outlook1.2 Global Transportation Management System (TMS) Solution Market Size Overview by Region 2016 VS 2021VS 20271.3 Global Transportation Management System (TMS) Solution Market Size by Region (2016-2027)1.4 Global Transportation Management System (TMS) Solution Historic Market Size by Region (2016-2021)1.5 Global Transportation Management System (TMS) Solution Market Size Forecast by Region (2022-2027)1.6 Key Regions, Transportation Management System (TMS) Solution Market Size YoY Growth (2016-2027)1.6.1 North America Transportation Management System (TMS) Solution Market Size YoY Growth (2016-2027)1.6.2 Europe Transportation Management System (TMS) Solution Market Size YoY Growth (2016-2027)1.6.3 Asia-Pacific Transportation Management System (TMS) Solution Market Size YoY Growth (2016-2027)1.6.4 Latin America Transportation Management System (TMS) Solution Market Size YoY Growth (2016-2027)1.6.5 Middle East & Africa Transportation Management System (TMS) Solution Market Size YoY Growth (2016-2027) 2 Transportation Management System (TMS) Solution Market Overview by Type2.1 Global Transportation Management System (TMS) Solution Market Size by Type: 2016 VS 2021 VS 20272.2 Global Transportation Management System (TMS) Solution Historic Market Size by Type (2016-2021)2.3 Global Transportation Management System (TMS) Solution Forecasted Market Size by Type (2022-2027)2.4 Planning and Execution2.5 Order Managment2.6 Audit, Payment and Claims2.7 Reporting and Analytics2.8 Routing and Tracking 3 Transportation Management System (TMS) Solution Market Overview by Application3.1 Global Transportation Management System (TMS) Solution Market Size by Application: 2016 VS 2021 VS 20273.2 Global Transportation Management System (TMS) Solution Historic Market Size by Application (2016-2021)3.3 Global Transportation Management System (TMS) Solution Forecasted Market Size by Application (2022-2027)3.4 Retail3.5 Healthcare and Pharmaceutical3.6 Manufacturing3.7 Transportation and Logistics3.8 Energy and Utilities3.9 Government3.10 Others 4 Transportation Management System (TMS) Solution Competition Analysis by Players4.1 Global Transportation Management System (TMS) Solution Market Size by Players (2016-2021)4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Transportation Management System (TMS) Solution as of 2020)4.3 Date of Key Players Enter into Transportation Management System (TMS) Solution Market4.4 Global Top Players Transportation Management System (TMS) Solution Headquarters and Area Served4.5 Key Players Transportation Management System (TMS) Solution Product Solution and Service4.6 Competitive Status4.6.1 Transportation Management System (TMS) Solution Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Oracle5.1.1 Oracle Profile5.1.2 Oracle Main Business5.1.3 Oracle Transportation Management System (TMS) Solution Products, Services and Solutions5.1.4 Oracle Transportation Management System (TMS) Solution Revenue (US$ Million) & (2016-2021)5.1.5 Oracle Recent Developments5.2 SAP5.2.1 SAP Profile5.2.2 SAP Main Business5.2.3 SAP Transportation Management System (TMS) Solution Products, Services and Solutions5.2.4 SAP Transportation Management System (TMS) Solution Revenue (US$ Million) & (2016-2021)5.2.5 SAP Recent Developments5.3 Manhattan Associates5.5.1 Manhattan Associates Profile5.3.2 Manhattan Associates Main Business5.3.3 Manhattan Associates Transportation Management System (TMS) Solution Products, Services and Solutions5.3.4 Manhattan Associates Transportation Management System (TMS) Solution Revenue (US$ Million) & (2016-2021)5.3.5 Trimble Recent Developments5.4 Trimble5.4.1 Trimble Profile5.4.2 Trimble Main Business5.4.3 Trimble Transportation Management System (TMS) Solution Products, Services and Solutions5.4.4 Trimble Transportation Management System (TMS) Solution Revenue (US$ Million) & (2016-2021)5.4.5 Trimble Recent Developments5.5 Blujay Solutions5.5.1 Blujay Solutions Profile5.5.2 Blujay Solutions Main Business5.5.3 Blujay Solutions Transportation Management System (TMS) Solution Products, Services and Solutions5.5.4 Blujay Solutions Transportation Management System (TMS) Solution Revenue (US$ Million) & (2016-2021)5.5.5 Blujay Solutions Recent Developments5.6 MercuryGate International5.6.1 MercuryGate International Profile5.6.2 MercuryGate International Main Business5.6.3 MercuryGate International Transportation Management System (TMS) Solution Products, Services and Solutions5.6.4 MercuryGate International Transportation Management System (TMS) Solution Revenue (US$ Million) & (2016-2021)5.6.5 MercuryGate International Recent Developments 6 North America6.1 North America Transportation Management System (TMS) Solution Market Size by Country (2016-2027)6.2 United States6.3 Canada 7 Europe7.1 Europe Transportation Management System (TMS) Solution Market Size by Country (2016-2027)7.2 Germany7.3 France7.4 U.K.7.5 Italy7.6 Russia7.7 Nordic7.8 Rest of Europe 8 Asia-Pacific8.1 Asia-Pacific Transportation Management System (TMS) Solution Market Size by Region (2016-2027)8.2 China8.3 Japan8.4 South Korea8.5 Southeast Asia8.6 India8.7 Australia8.8 Rest of Asia-Pacific 9 Latin America9.1 Latin America Transportation Management System (TMS) Solution Market Size by Country (2016-2027)9.2 Mexico9.3 Brazil9.4 Rest of Latin America 10 Middle East & Africa10.1 Middle East & Africa Transportation Management System (TMS) Solution Market Size by Country (2016-2027)10.2 Turkey10.3 Saudi Arabia10.4 UAE10.5 Rest of Middle East & Africa 11 Transportation Management System (TMS) Solution Market Dynamics11.1 Industry Trends11.2 Market Drivers11.3 Market Challenges11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Disclaimer13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Here is the original post:

Transportation Management System (TMS) Solution Market Size, Share, Trend, Growth Analysis, COVID-19 Impact, Forecast 2021-2027 | Oracle, SAP,...

Date: 2021-04-01 Author: Ashwin NaphadeCategory: #news

Global Treasury Management System (TMS) market report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

An in-depth analysis of the Treasury Management System (TMS) market has been enlisted in this research report, in conjunction with an evaluation of numerous driving factors. As per the Treasury Management System (TMS) market study, this industry vertical is estimated to accrue substantial proceeds by the end of the projected duration. Additionally, the report delivers a detailed analysis pertaining to the industry segmentation, apart from a generic outline of this industry subject to the current market scenario. Information about the Treasury Management System (TMS) market with respect to the industry size has also been provided, conjointly with the regional expanse of the business.

Request a sample Report of Treasury Management System (TMS) Market at:https://www.marketstudyreport.com/request-a-sample/2700818?utm_source=algosonline.com&utm_medium=SK

A precise gist of how far the scope of the Treasury Management System (TMS) market traverses:

A generic overview of the competitive landscape:

Ask for Discount on Treasury Management System (TMS) Market Report at:https://www.marketstudyreport.com/check-for-discount/2700818?utm_source=algosonline.com&utm_medium=SK

An in-depth outline of the regional expanse:

A succinct summary of the industry segmentation:

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-impact-on-global-treasury-management-system-tms-market-size-status-and-forecast-2020-2026

Related Reports:

1. Global Pre-Warehouse Mode Store Key Trends and Opportunities to 2027Read More: https://www.marketstudyreport.com/reports/global-pre-warehouse-mode-store-key-trends-and-opportunities-to-2027

2. Global Fresh Supermarket Key Trends and Opportunities to 2027Read More: https://www.marketstudyreport.com/reports/global-fresh-supermarket-key-trends-and-opportunities-to-2027

Related Report : https://www.marketwatch.com/press-release/global-nerve-monitoring-system-market-analysis-with-key-players-applications-trends-and-forecasts-to-2025-2021-03-31

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Link:

Treasury Management System (TMS) Market Trend, Technology Innovations and Growth Prediction 2020-2026 - AlgosOnline

DataIntelo published a detailed report on Global Treasury Management System (TMS) Market for the clients that wants to explore new market avenues, get in-depth insights on the market products, maximize their revenue, and review the strategies implemented by prominent players in the market.

Key Players of the Treasury Management System (TMS) Market

OracleFinastraSalmon Software LimitedACI WorldwideGTreasuryBroadridge Financial SolutionsGresham TechnologiesPath SolutionsTauliaInvestopediaIntimusPECNextageCash Management SolutionsSopra BankingNational Cash Management Systems (NCMS)Giesecke & Devrient GmbHAURIONPRONTT DATA EMEA Ltd.Glory Global SolutionsALVARA Cash Management Group AGBankSeneSAPIBSFINtech

Get Sample of the Treasury Management System (TMS) Report https://dataintelo.com/request-sample/?reportId=184322

Major Highlights of the Treasury Management System (TMS) Market Report

The research team at DataIntelo has proximately monitored the market since 2017. During the time, the team has covered the factors that are expected to boost the market performance and impede the growth of the market during the forecast period, 2020-2027. Additionally, it has enlisted the challenges faced by key market players, new entrants, and emerging players in the market.

What is Covered in the Chapter of Impact of COVID-19 Pandemic?

The coronavirus pandemic has disrupted the market dynamics, as it had imposed the restriction on the opening of offices and manufacturing facilities. This, in turn, has persuaded employees to work from home and halted the production of goods across the globe. Moreover, it had increased the gap between demand and supply owing to the restricted trade affairs around the world. However, it has created lucrative opportunities for the key players in certain regions.

The COVID-19 chapter of Treasury Management System (TMS) Market includes:

What is Covered in The Segmentation Part of The Treasury Management System (TMS) Report?

Products

Local SystemsCloud-Hosted SystemsOthers

Applications

Large EnterprisesSMEsGovernmentOthers

Regions

Note: Can add country of your choice in the report at no extra cost.

The segmentation part of the report covers:

This segmentation provides the esteemed reader with the comprehensive regional analysis, which includes if the region/country has a potential worth of investment. This analysis is prepared by considering the socio-economic development and government regulations & policies of the country.

Buy the Complete Report https://dataintelo.com/checkout/?reportId=184322

Note: Additional company names can be added in the list.

The report covers the major players of the market and provides information about their product portfolio and strategies deploying regarding the market. This market report includes technological advancements of products by the key players. It lays out the information on collaborations, partnerships, mergers, and agreements carried out by industry players over the years in the market. Furthermore, it covers the factors that have created opportunities and challenges for them.

7 Reasons to Buy Report from DataIntelo

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Treasury Management System (TMS) Market Overview

Global Treasury Management System (TMS) Market Analysis and Forecast by Type

Global Treasury Management System (TMS) Market Analysis and Forecast by Application

Global Treasury Management System (TMS) Market Analysis and Forecast by Sales Channel

Global Treasury Management System (TMS) Market Analysis and Forecast by Region

North America Treasury Management System (TMS) Market Analysis and Forecast

Latin America Treasury Management System (TMS) Market Analysis and Forecast

Europe Treasury Management System (TMS) Market Analysis and Forecast

Asia Pacific Treasury Management System (TMS) Market Analysis and Forecast

Asia Pacific Treasury Management System (TMS) Market Size and Volume Forecast by Application

Middle East & Africa Treasury Management System (TMS) Market Analysis and Forecast

Competition Landscape

If you have any inquiry of the report, connect with our analyst @ https://dataintelo.com/enquiry-before-buying/?reportId=184322

About DataIntelo

DataIntelo has extensive experience in the creation of tailored market research reports in several industry verticals. We cover in-depth market analysis which includes producing creative business strategies for the new entrants and the emerging players of the market. We take care that our every report goes through intensive primary, secondary research, interviews, and consumer surveys. Our company provides market threat analysis, market opportunity analysis, and deep insights into the current and market scenario.

To provide the utmost quality of the report, we invest in analysts that hold stellar experience in the business domain and have excellent analytical and communication skills. Our dedicated team goes through quarterly training which helps them to acknowledge the latest industry practices and to serve the clients with the foremost consumer experience.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 414 1393

Email:[emailprotected]

Website:https://dataintelo.com

More here:

Treasury Management System (TMS) Market to Witness Strong Growth Over 2021-2027 | Key Manufacturers Overview- Oracle, Finastra, Salmon Software...

CLARK COUNTY Since the beginning of the pandemic, the number of people showing symptoms and seeking help for depression has skyrocketed. A recent study found that four out of 10 adults have reported symptoms of anxiety or depressive disorder; a four-fold increase from pre-COVID life.

Kaiser Family Foundation analyzed the U.S. Census Bureaus Household Pulse Survey and found the prevalence of mental illness in Washington increased significantly in the last year. To provide additional treatment options to address this growing crisis, Active Recovery TMS, an Oregon-based mental health clinic specializing in transcranial magnetic stimulation (TMS) to treat depression, is opening its sixth location in Vancouver in April.

Active Recovery TMS is currently accepting patients for its new clinic located in the Columbia Tech Center, Building 608, 1499 SE Tech Center PL, Suite 170. The clinic will provide people struggling with severe depression who havent responded to medication or talk therapy with a valuable option for managing their mental health.

TMS can reduce symptoms of depression or bring it under control with minimal side effects. It is an FDA-cleared treatment covered by most commercial insurance plans, Medicare, Medicaid, the VA, and Tri-Care/Tri-West.

The World Health Organization found that by 2035, its predicted that depression will be the worlds number one cause of morbidity, says Pritham Raj, MD, FACP, a psychiatrist at Active Recovery TMS. When I began exploring TMS, I saw great results coming from the research studies on patients and their remission, and I was pleased to see people getting help with such mild side-effects and little or no medication.

Active Recovery TMS currently has five locations across the Portland-metro area and greater Willamette Valley. In addition to the clinic in northwest Portland, last year, the company opened clinics in Hillsboro, Tigard, Salem, and most recently, Clackamas.

The demand for the clinics services continues to increase. Over the past year, the practice has nearly doubled its size, adding 12 new hires, including psychiatric nurse practitioners and technicians.

Our goal is to improve access to this breakthrough treatment for all patients in our region. Expanding into Washington state has been a goal of ours for a long time. We are now able to offer this treatment to patients in southwest Washington, many who have been traveling to Portland every week, said David Grano, CEO of Active Recovery TMS. Because this treatment is performed daily, the proximity of clinics to our patients work and home is imperative.

While a provider referral for services is not required, the clinics work with providers to design treatment plans and confirm insurance coverage for the procedures.

TMS uses a highly focused, pulsed magnetic field (similar to an MRI) to target the brain regions involved in regulating mood. Each treatment is approximately 20 minutes, five days a week for six weeks. While antidepressant medications may affect sleep or cognition, TMS causes minimal side effects in a small percentage of patients. The therapy is administered on an outpatient basis so that patients can resume their normal activities immediately following treatment.

The National Institute of Mental Health reports that depression is one of the most common mental disorders in the U.S. An estimated 17.3 million adults, or 7.1 percent of all U.S. adults, suffered from at least one major depressive episode in 2017. Studies now show that number has grown several-fold as a result of the pandemic.

Based on an internal review of patient outcomes, 79 percent of Active Recovery TMS patients have shown a measurable decrease in depression symptoms. These results are reported on the Patient Health Questionnaire 9 (PHQ-9; a commonly used depression scale), and one-third achieve control of their depression and are free from symptoms. These numbers echo more rigorous national studies conducted in clinical settings.

Active Recovery TMS strives to be a compelling option for those who have not had success with standard depression treatments like medication and psychotherapy. Active Recovery TMS has been treating patients since 2017. Call (503) 966-1132 or visit activerecoverytms.com for more information.

Go here to read the rest:

Active Recovery TMS opens sixth clinic in the Vancouver area | ClarkCountyToday.com - clarkcountytoday.com

Bloomberg

(Bloomberg) -- From his perch high above Midtown Manhattan, just across from Carnegie Hall, Bill Hwang was quietly building one of the worlds greatest fortunes.Even on Wall Street, few ever noticed him -- until suddenly, everyone did.Hwang and his private investment firm, Archegos Capital Management, are now at the center of one of the biggest margin calls of all time -- a multibillion-dollar fiasco involving secretive market bets that were dangerously leveraged and unwound in a blink.Hwangs most recent ascent can be pieced together from stocks dumped by banks in recent days -- ViacomCBS Inc., Discovery Inc. GSX Techedu Inc., Baidu Inc. -- all of which had soared this year, sometimes confounding traders who couldnt fathom why.One part of Hwangs portfolio, which has been traded in blocks since Friday by Goldman Sachs Group Inc., Morgan Stanley and Wells Fargo & Co., was worth almost $40 billion last week. Bankers reckon that Archegoss net capital -- essentially Hwangs wealth -- had reached north of $10 billion. And as disposals keep emerging, estimates of his firms total positions keep climbing: tens of billions, $50 billion, even more than $100 billion.It evaporated in mere days.Ive never seen anything like this -- how quiet it was, how concentrated, and how fast it disappeared, said Mike Novogratz, a career macro investor and former partner at Goldman Sachs whos been trading since 1994. This has to be one of the single greatest losses of personal wealth in history.Late Monday in New York, Archegos broke days of silence on the episode.This is a challenging time for the family office of Archegos Capital Management, our partners and employees, Karen Kessler, a spokesperson for the firm, said in an emailed statement. All plans are being discussed as Mr. Hwang and the team determine the best path forward.The cascade of trading losses has reverberated from New York to Zurich to Tokyo and beyond, and leaves myriad unanswered questions, including the big one: How could someone take such big risks, facilitated by so many banks, under the noses of regulators the world over?One part of the answer is that Hwang set up as a family office with limited oversight and then employed financial derivatives to amass big stakes in companies without ever having to disclose them. Another part is that global banks embraced him as a lucrative customer, despite a record of insider trading and attempted market manipulation that drove him out of the hedge fund business a decade ago.A disciple of hedge-fund legend Julian Robertson, Sung Kook Bill Hwang shuttered Tiger Asia Management and Tiger Asia Partners after settling an SEC civil lawsuit in 2012 accusing them of insider trading and manipulating Chinese banks stocks. Hwang and the firms paid $44 million, and he agreed to be barred from the investment advisory industry.He soon opened Archegos -- Greek for one who leads the way -- and structured it as a family office.Family offices that exclusively manage one fortune are generally exempt from registering as investment advisers with the U.S. Securities and Exchange Commission. So they dont have to disclose their owners, executives or how much they manage -- rules designed to protect outsiders who invest in a fund. That approach makes sense for small family offices, but if they swell to the size of a hedge fund whale they can still pose risks, this time to outsiders in the broader market.This does raise questions about the regulation of family offices once again, said Tyler Gellasch, a former SEC aide who now runs the Healthy Markets trade group. The question is if its just friends and family why do we care? The answer is that they can have significant market impacts, and the SECs regulatory regime even after Dodd-Frank doesnt clearly reflect that.Valuable CustomerArchegos established trading partnerships with firms including Nomura Holdings Inc., Morgan Stanley, Deutsche Bank AG and Credit Suisse Group AG. For a time after the SEC case, Goldman refused to do business with him on compliance grounds, but relented as rivals profited by meeting his needs.The full picture of his holdings is still emerging, and its not clear what positions derailed, or what hedges he had set up.One reason is that Hwang never filed a 13F report of his holdings, which every investment manager holding more than $100 million in U.S. equities must fill out at the end of each quarter. Thats because he appears to have structured his trades using total return swaps, essentially putting the positions on the banks balance sheets. Swaps also enable investors to add a lot of leverage to a portfolio.Morgan Stanley and Goldman Sachs, for instance, are listed as the largest holders of GSX Techedu, a Chinese online tutoring company thats been repeatedly targeted by short sellers. Banks may own shares for a variety of reasons that include hedging swap exposures from trades with their customers.Unhappy InvestorsGoldman increased its position 54% in January, according to regulatory filings. Overall, banks reported holding at least 68% of GSXs outstanding shares, according to a Bloomberg analysis of filings. Banks held at least 40% of IQIYI Inc, a Chinese video entertainment company, and 29% of ViacomCBS -- all of which Archegos had bet on big.Im sure there are a number of really unhappy investors who have bought those names over the last couple of weeks, and now regret it, Doug Cifu, chief executive officer of electronic-trading firm Virtu Financial Inc., said Monday in an interview on Bloomberg TV. He predicted regulators will examine whether there should be more transparency and disclosure by a family office.Without the need to market his fund to external investors, Hwangs strategies and performance remained secret from the outside world. Even as his fortune swelled, the 50-something kept a low profile. Despite once working for Robertsons Tiger Management, he wasnt well-known on Wall Street or in New York social circles.Hwang is a trustee of the Fuller Theology Seminary, and co-founder of the Grace and Mercy Foundation, whose mission is to serve the poor and oppressed. The foundation had assets approaching $500 million at the end of 2018, according to its latest filing.Its not all about the money, you know, he said in a rare interview with a Fuller Institute executive in 2018, in which he spoke about his calling as an investor and his Christian faith. Its about the long term, and God certainly has a long-term view.His extraordinary run of fortune turned early last week as ViacomCBS Inc. announced a secondary offering of its shares. Its stock price plunged 9% the next day.The value of other securities believed to be in Archegos portfolio based on the positions that were block traded followed.By Thursdays close, the value of the portfolio fell 27% -- more than enough to wipe out the equity of an investor who market participants estimate was six to eight times levered.Its also hurt some of the banks that served Hwang. Nomura and Credit Suisse warned of significant losses in the wake of the selloff and Mitsubishi UFJ Financial Group Inc. has flagged a potential $300 million loss.You have to wonder who else is out there with one of these invisible fortunes, said Novogratz. The psychology of all that leverage with no risk management, its almost nihilism.(Updates with latest bank to detail exposure in penultimate paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.2021 Bloomberg L.P.

Link:

EDAP TMS S.A. (EDAP) Stock Jumps 18.8%: Will It Continue to Soar? - Yahoo Finance

A new study tested transcranial magnetic stimulation (TMS) for treating people with a bipolar disorder diagnosis. The researchers found that actual TMS was no better than a sham (fake) treatment.

The study was led by Lakshmi N. Yatham at the University of British Columbia Hospital in Canada and published in JAMA Network Open.

The specific type of intervention used is intermittent theta-burst stimulation (iTBS), a type of TMS. The researchers targeted the left dorsolateral prefrontal cortex (LDPC) in the brain. The goal was to relieve depression symptoms in people diagnosed with bipolar disorder.

iTBS was used, and the LDPC was targeted because these are currently popular TMS methods in depression treatment. Yatham writes:

There was no evidence of antidepressant superiority for active iTBS over sham iTBS, and safety is uncertain because 1 hypomanic switch occurred with active iTBS and a second occurred during the open-label phase.

That is, people randomly assigned to the fake treatment did just as well as people who received actual iTBS. Additionally, two people undergoing actual iTBS became hypomaniccompared with none who were receiving the sham treatment.

The study was double-blinded, meaning that neither the participants nor the researchers knew who was receiving iTBS and who was receiving the sham treatment. The randomized, controlled trial lasted for four weeks, with an additional four-week open-label phase during which there was no sham control group.

The 37 participants were required to have a diagnosis of bipolar disorder I or II, be currently experiencing a major depressive episode, and be currently taking a mood stabilizer and/or an antipsychotic drug. They were also required to have had no clinical response to the drugthat is, for the participants in this study, mood stabilizers and antipsychotics did not work to improve their symptoms.

People who had previously had no response to TMS were excluded, as were people who were suicidal, experiencing psychosis or substance abuse, or undergoing psychotherapy.

The study was intended to include 50 people in each group (totaling 100). However, the study was canceled early because TMS was so inadequate. Response rates were very low: 3 of the 19 people in the sham treatment group improved, while 3 of the 18 people in the active treatment group improved.

After eight participants dropped out, 29 participants completed the four-week randomized trial. 21 people then agreed to enter the open-label phase. Five of them dropped out, leaving 16 people to complete the open-label trial. Four of the 16 remaining people achieved clinical remission during the open-label phasebut there was no control group to compare these results to, so they could also have been due to the placebo effect or regression to the mean.

Although the researchers write that blinding integrity was preserved, they note that about half of the people in the study correctly guessed whether they received the active treatment or not. Additionally, people were far more likely to improve if they believed they had received the active treatmentwhich is evidence of a strong placebo effect.

Surprisingly, TMS is approved by the FDA for the treatment of depression for people with any diagnosis, including bipolar disorder. The researchers note that this is based on extrapolating findings from studies on people with a depression diagnosis rather than any actual evidence on bipolar disorder.

Nonetheless, this isnt the first study to demonstrate the ineffectiveness of TMS. A 2016 sham-controlled study of a different type of TMS (sequential bilateral repetitive transcranial magnetic stimulation) similarly found that the active treatment was ineffective in those with a bipolar disorder diagnosis.

Even in the treatment of people with a depression diagnosis rather than bipolar disorder, the evidence for the effectiveness of TMS is unclear. Three large, multisite trials found that TMS was ineffective.

A review by the Clinical TMS Society frames these findings positively, but the results are clear:

****

McGirr, A., Vila-Rodriguez, F., Cole, J., Torres, I. J., Arumugham, S. S., Keramatian, K., . . . & Yatham, L. N. (2021). Efficacy of active vs. sham intermittent theta-burst transcranial magnetic stimulation for patients with bipolar depression: A randomized clinical trial. JAMA Netw Open, 4(3), e210963. doi:10.1001/jamanetworkopen.2021.0963 (Link)

Go here to read the rest:

Transcranial Magnetic Stimulation (TMS) Ineffective for People with Bipolar Disorder - James Moore

Despite its proven efficacy for unipolar depression, intermittent theta burst transcranial magnetic stimulation (iTBS) appears to be ineffective in alleviating symptoms of bipolar depression, new research suggests.

Overall, investigators found that only 16% of participants responded to iTBS during the double-blind period of the trial, and the proportion of patients who responded to iTBS was the same as the proportion who responded to sham treatment. Moreover, in the open-label period of the study, only 24% of patients met the criteria for response. The trial was terminated early for futility.

"If a treating clinician decides to offer TMS to a bipolar depressed patient, we suggest that clinicians refrain from offering iTBS," senior author Lakshmi Yatham, MBBS, MBA, professor and head, Department of Psychiatry, and director of the Institute of Mental Health, University of British Columbia, Vancouver, Canada, told Medscape Medical News.

"Instead, we would advocate using traditional forms of TMS, such as HFS [high-frequency stimulation] to the left dorsolateral prefrontal cortex or LFS [low-frequency stimulation] to the right dorsolateral prefrontal cortex," said Yatham, who is also the president of the World Federation of Societies of Biological Psychiatry and the editor-in-chief of The Canadian Journal of Psychiatry.

The study was published online March 12 in JAMA Network Open.

Repetitive TMS (rTMS), a noninvasive neurostimulation treatment, is a first-line intervention in pharmacotherapy-resistant unipolar major depressive disorder (MDD).

Newer TMS protocols that use theta burst stimulation have "garnered significant research attention and evidence for antidepressant efficacy," the authors write. iTMS, in particular, has been shown to produce "lasting neurophysiological changes" and "antidepressant efficacy in MDD." Despite the "growing evidence base" supporting the use of iTBS for MDD, there has been insufficient research in the use of this modality for patients with bipolar depression.

"A meta-analysis we had conducted with data on a small number of bipolar patients who had participated in previous TMS trials showed that TMS is likely beneficial," said Yatham.

"Given that theta burst stimulation requires much less time commitment for patients, and given that this form of stimulation has shown benefit in unipolar depression, we wanted to test if this treatment would work for bipolar depression, especially because there are very few safe and effective treatments for this patient population," she said.

The researchers randomly assigned 37 patients with bipolar depression to receive either active iTBS that targeted the left dorsolateral prefrontal cortex or sham iTBS (n = 18 and n = 19, respectively). The patients were between the ages of 20 and 68 years (mean age, 43.86; 62% women). The patients had experienced no clinical response to 1 first-line treatments for an acute major depressive episode (MDE).

Patients who were acutely suicidal, who were experiencing psychosis, who had recently been diagnosed with a substance use disorder, or who had a variety of other medical or psychiatric comorbidities were excluded from the trial.

Patients who did not exhibit 50% reduction in score on the Montgomery-sberg Depression Rating Scale (MADRS) at the conclusion of the double-blind phase of the study were offered an additional 4 weeks of open-label iTBS.

The group that received sham treatment and the active-treatment group presented with similar baseline levels of depression of moderate severity (MADRS scores, 32.57 [mean SD, 4.00] and 33.38 [mean SD, 4.46], respectively).

During the double-blind phrase, two participants who were receiving iTBS and four participants who were receiving sham iTBS dropped out of the study; one participant in the active-iTBS group discontinued treatment after 3 weeks because of COVID-19-related institutional closures; and one participant in the active-iTBS group experienced a mood switch after the first treatment session.

The researchers found "no evidence for clinical superiority" of active iTBS in comparison with sham iTBS. There was no significant difference between the two groups in change of mean score on the MADRS (P = .91).

In fact, the least squares mean difference for MADRS scores at week 4 was -1.36 (95% CI, -8.92 to 6.19; P = .91) in favor of sham iTBS.

There were no differences in improvement between the groups with respect to use of different mood stabilizers, and there were no differences in rates of clinical response at the conclusion of the double-blind phase of the study.

There were no differences between the two groups in self-reported depressive or anxiety symptoms following the intervention.

Of the 29 participants who completed the double-blind phase of the trial, 21 entered the open-label phase. Of these, 16 completed all 4 weeks of treatment.

After the double-blind phase, five patients in the open-label phase of the trial achieved clinical response, and four achieved clinical remission (23.8% and 19.0%, respectively). Of the five patients who experienced clinical response, three had been allocated to the sham-iTBS condition during the double-blind phase.

rTMS has been shown to be effective for unipolar depression but not for bipolar depression, because "these two conditions are likely biologically different," said Yatham.

"There are examples of other treatments that have worked in unipolar but not in bipolar depression for instance, commonly used antidepressants such as SSRIs [selective serotonin reuptake inhibitors] work very well for unipolar depression, but their efficacy in bipolar depression remains unproven," she said.

Commenting on the study for Medscape Medical News, Scott Aaronson, MD, director of clinical research, Shepherd Pratt, Towson, Maryland, expressed concern "that people might extrapolate data from this study to think that TMS doesnt work for bipolar depression."

Aaronson, an adjunct professor at the University of Maryland School of Medicine, Baltimore, Maryland, who was not involved with the study, said the investigators "have come to the right conclusion, which is the tendency for all of us to look at all TMS techniques as the same."

In an accompanying commentary, Joan Camprodon, MD, MPH, PhD, chief of the Division of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, said the study "emphasizes the need to deepen our characterization of circuit pathophysiology, the identification of anatomical treatment targets, and the focus on oscillatory physiological dynamics to understand both disease mechanisms and the distinct mechanisms of action (and clinical indications) of different TMS frequency interventions."

The study was supported by a philanthropic donation through the University of British Columbia.Yatham has received honoraria or research grants from Allergan, CANMAT, Lundbeck, Otsuka, DSP, Sanofi, Intracellular Therapies, AbbVie, Merck, and Sunovion. The other authors' disclosures are listed on the original article. Camprodon has served on the scientific advisory board of Hyka and Feelmore Labs and has received consultation honoraria from Neuronetics. His research is currently funded by the National Institutes of Health, the AE foundation, the Solinsky Foundation, and the Gerstner foundation. Aaronson is a consultant for I Neuronetics, a company that makes TMS devices.

JAMA Netw Open. Published online March 12, 2021. Full text, Commentary

For more Medscape Psychiatry news, join us on Facebook and Twitter.

View original post here:

New Efficacy Data on Theta Burst TMS for Bipolar Depression - Medscape

Sandhya Prashad, MD is medical director at Houston Ketamine Therapeutics and Houston Deep Transcranial Magnetic Stimulation (TMS) Therapy.

There is no question that the pandemic has shaped myriad aspects of life as we know it, including significantly impacting the mental health care industry. While the unprecedented events have resulted in mental health challenges, it has also delivered growth in the area as well.

In fact, the appetite for treatment has increased so much that providers are finding it challenging to accommodate the surge of requested appointments.1 This new found openness among patients to explore therapy has served as a means to deliver more care to those who have lived in silence for years due to either apprehension around going into an office or limited understanding around just how far treatment options have come.

Teletherapy has helped shepherd more patients through the door

Leveraging teletherapy has helped providers and patients troubleshoot the common concerns around social distancing and, ultimately, could be credited with getting many first-time patients in the virtual door. In fact, the use of teletherapy saw a 154% increase in March 2020 when compared to the same period in 2019.2 The ability to connect with patients in the comfort and privacy of their own homes allowed providers to build rapport over time and helped spark many overdue conversations around tailored options for treatment. While the convenience of teletherapy is likely to foster continued use long after the pandemic subsides, it is important for providers to remind patients that it is not a direct substitute for an in-person visit nor is it the only form of treatment available.

Taking the next step in treatment with the latest technology

Marrying the increased desire to speak with providers and the ability to ease into sessions via virtual visits, providers like myself have a unique opportunity to begin educating patients that mental health treatment is not a one-size-fits-all approach. Studies have shown that depression symptom prevalence is more than 3-fold higher3 during the COVID-19 pandemic, and because more than 40% of people with major depressive disorder (MDD)4 find they are treatment-resistant, there is a growing need to foster education among patients regarding other available options when there is an unresponsiveness to traditional methods.5 These options include deep transcranial magnetic stimulation (Deep TMS), a noninvasive treatment process that is FDA-cleared for treating depression and obsessive-compulsive disorder (OCD). While well-known within the mental health community, many patients are unaware of this successful treatment option which only takes 20-minutes per session.

In a study published by the Journal of Psychiatric Research, Deep TMS therapy combined with standard medication for MDD was found to be significantly more effective than standard pharmacotherapy alone, reducing the symptoms of close to two-thirds of participants battling depression.6 Deep TMS is a great example of how far we have come in treatment offerings, showing patients that there are treatments that do not require downtime, are noninvasive, and offer virtually no discomfort.

Moving forward in the new normal

While we as a society are working hard to leave the pandemic behind as a footnote in history, we as mental health professionals have been given a catalyst for a mental health movement. The pandemic has helped break down barriers such as the stigma around treatment, access to care in terms of proximity and available time, and even common misconceptions of what it means to receive treatment for depression. It is our responsibility as those committed to improving mental health to look for every opportunity we can to serve and educate, and the pandemic has certainly provided us with a platform.

Sandhya Prashad, MD is a board-certified psychiatrist specializing in interventional modalities for treatment-resistant disorders with a particular interest and expertise in ketamine therapy. She is the founder and medical director of Sandhya J. Prashad, MD, Houston Ketamine Therapeutics, and Houston TMS Therapeutics. Dr Prashad currently serves as president of The American Society of Ketamine Physicians, Psychotherapists and Practitioners.

References

1. Caron C. Nobody Has Openings: Mental Health Providers Struggle to Meet Demand. The New York Times. https://www.nytimes.com/2021/02/17/well/mind/therapy-appointments-shortages-pandemic.html. Published online February 17, 2021. Accessed February 17, 2021

2. Koonin LM, Hoots B, Tsang CA, et al. Trends in the use of telehealth during the emergence of the COVID-19 pandemic United States, JanuaryMarch 2020. MMWR Morb Mortal Wkly Rep. 2020;69:15951599. doi:10.15585/mmwr.mm6943a3

3. Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Netw Open. 2020;3(9):e2019686. doi:10.1001/jamanetworkopen.2020.19686

4. Major Depressive Disorder and TMS Treatment. Brainsway. https://www.brainsway.com/knowledge-center/major-depressive-disorder-tms-treatment/. Accessed February 9, 2019

5. Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 19, 247 (2019). doi:10.1186/s12888-019-2222-4

6. Filipi I, imunovi Filipi I, Milovaca Z, et al. Efficacy of repetitive transcranial magnetic stimulation using a figure-8-coil or an H1-Coil in treatment of major depressive disorder; A randomized clinical trial. J. Psychiatr. Res. 2019;114:113-119. doi:10.1016/j.jpsychires.2019.04.020

Read this article:

The COVID-19 Pandemic: Helping Those Who Suffer in Silence - Psychiatry Advisor

DataIntelo has published a latest report on Global Transcranial Magnetic Stimulators (TMS) Market report. This report has been prepared by primary interviews and secondary research methodology. The market report provides detailed insights on the product pricing & trends, market drivers, and potential lucrative opportunities, during the forecast period, 2020-2027. Additionally, it covers market challenges and threats faced by companies.

Competitive Landscape

The market report provides information about the companys product, sales in terms of volume and revenue, technologies utilized, and innovations carried out in recent years. Additionally, it provides details on the challenges faced by them in the market.

The major players of the Transcranial Magnetic Stimulators (TMS) market are:

YiruideNeuroneticsMagstimBrainswayMagVentureeNeuraRemedNeurosoftDr. Langer MedicalNexstimYiruide

Note: Additional or specific companies can be profiled in the list at no extra cost.

Get free sample report @ https://dataintelo.com/request-sample/?reportId=164413

During the preparation of the report, the research team conducted several interviews with key designated executives and experts of the market. This, in turn, has helped them to understand the overall scope and complex matrix of the Transcranial Magnetic Stimulators (TMS) market. The market research report includes crucial data and figures about the report that aids the esteemed reader to make crucial business decisions. These data and figures are added in a concise manner in form of infographics and tables to save time.

Transcranial Magnetic Stimulators (TMS) Market Report Gives Out FREE COVID-19 Chapter

The COVID-19 pandemic had forced government state bodies across the globe to impose lockdown, which in turn, derailed the entire economy. Manufacturing facilities, schools, colleges, and offices witnessed a complete shutdown for few months in 2020. This resulted in the slowdown in the sales of products, which majorly impacted the growth rate of the market. Conversely, new market opportunities were explored and indeed created lucrative opportunities for the industry players.

The COVID-19 chapter covers the impact of pandemic on the market in a detailed manner. This includes product launches and strategies implemented by the industry players in the trying times. It discusses new market avenues, revenue drivers, untapped opportunities, and top-winning strategies in the market.

The research team has monitored the market closely in COVID-19 pandemic and conducted interviews with the market experts to understand the impact of coronavirus pandemic on the Transcranial Magnetic Stimulators (TMS) market. Moreover, the market provides information on the long-term challenges industry players is anticipated to face due to the pandemic.

Buy the complete report @ https://dataintelo.com/checkout/?reportId=164413

In-depth Insights on the Market Segments

The market segmentation are the vital fragments of the market. This report covers the types of the products available in the market, their applications and end-uses. Moreover, it includes the regional landscape of the market.

This part of the report covers the raw materials used for the products, supply & demand scenario, and potential applications of the products in the coming years. The market segmentation also provides in-depth insights on the regional market performance. This means that the regional landscape covers products sales in terms of volume and revenue from 2017 to 2020. Moreover, it provides insights on the expected performance of the product segment during the forecast period.

The global Transcranial Magnetic Stimulators (TMS) report gives in detailed insights on the regional landscape, which involves determining the potential of worth of investment in the particular region/country. Moreover, it gives out information about the market share of the industry players in the particular region.

Products

STMSPTMSRTMSnTMS

Applications

DepressionTinnitusAlzheimerParkinsons DiseasePsychiatric DisordersHeadacheStroke

Regions

North AmericaEuropeAsia PacificMiddle East & AfricaLatin America

Note: Country of your choice can be added at no extra cost. However, if one more than country needs to be added in the list, the research quote will vary accordingly.

The complete Transcranial Magnetic Stimulators (TMS) report can be tailored according to the clients requirements.

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Transcranial Magnetic Stimulators (TMS) Market Overview

Global Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast by Type

Global Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast by Application

Global Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast by Sales Channel

Global Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast by Region

North America Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast

Latin America Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast

Europe Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast

Asia Pacific Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast

Asia Pacific Transcranial Magnetic Stimulators (TMS) Market Size and Volume Forecast by Application

Middle East & Africa Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast

Competition Landscape

If you have any doubts regarding the report @ https://dataintelo.com/enquiry-before-buying/?reportId=164413

About DataIntelo

DataIntelo has extensive experience in the creation of tailored market research reports in several industry verticals. We cover in-depth market analysis which includes producing creative business strategies for the new entrants and the emerging players of the market. We take care that our every report goes through intensive primary, secondary research, interviews, and consumer surveys. Our company provides market threat analysis, market opportunity analysis, and deep insights into the current and market scenario.

To provide the utmost quality of the report, we invest in analysts that hold stellar experience in the business domain and have excellent analytical and communication skills. Our dedicated team goes through quarterly training which helps them to acknowledge the latest industry practices and to serve the clients with the foremost consumer experience.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Excerpt from:

Transcranial Magnetic Stimulators (TMS) Market 2021 Will Reflect Significant Growth in Future with Size, Share, Growth, and Key Companies Analysis-...

The market has been high on Edap Tms SA (EDAP) stock recently. EDAP gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.

InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.

Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

Edap Tms SA (EDAP) stock is trading at $9.34 as of 12:34 PM on Tuesday, Mar 30, a loss of -$0.34, or -3.55% from the previous closing price of $9.68. The stock has traded between $9.02 and $9.75 so far today. Volume today is 352,472 compared to average volume of 291,615.

To see InvestorsObserver's Sentiment Score for Edap Tms SA click here.

Edap TMS SAis a holding company operating in two divisions namely, High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU division develops, manufactures and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets two HIFU devices: the Ablatherm, treatment of organ-confined prostate cancer; and the Focal One, for the focal therapy of localized prostate cancer destroying targeted cancer cells only. The UDS division develops, markets, manufactures and services medical devices for the invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The business of the presence of the firm are sen Asia, France, United States and other regions.

Click Here to get the full Stock Score Report on Edap Tms SA (EDAP) Stock.

Excerpt from:

Where Will Edap Tms SA (EDAP) Stock Go Next After It Is Higher By 19.44% in a Week? - InvestorsObserver